99mTechnetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7–14) as a Targeted Imaging Agent with MicroSPECT in a PC-3 Prostate Cancer Xenograft Model
- 30 June 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 8 (4) , 1165-1173
Abstract
The peptide bombesin (BN) and derivates thereof show high binding affinity for the gastrin-releasing peptide receptor (GRPR), which is highly expressed in primary and metastasized prostate cancer. We have synthesized a new BN-based radiopharmaceutical 99mtechnetium-HYNIC(tricine/TPPTS)-Aca-BN(7–14) (99mTc-HABN) and evaluated its GRPR targeting properties in vitro and in a xenograft tumor model for human prostate cancer in athymic mice. 99mTc-HABN was synthesized, and its lipophilicity and stability were investigated. The IC50, internalization and efflux properties were determined in vitro using the GRPR expressing human prostate cancer cell line PC-3. 99mTc-HABN biodistribution and microSPECT imaging were performed in PC-3 tumor-bearing athymic mice. 99mTc-HABN was prepared with high labeling yield (>90%), high radiochemical purity (>95%) and a specific activity of ∼19.8 MBq/nmol. The partition coefficient log D value was −1.60 ± 0.06. 99mTc-HABN proved to be stable in human serum for 6 h. The IC50 of HYNIC-Aca-BN(7–14) was 12.81 ± 0.14 nM. Incubation of PC-3 cells with 99mTc-HABN demonstrated rapid cellular internalization and a long intracellular retention time. When mice were injected with 99mTc-HABN, the activity was predominantly cleared via the kidneys. Uptake in the tumor was 2.24 ± 0.64% ID/g after 30 min, with a steady decrease during the 4 h study period. In vivo experiments with a blocking agent showed GRPR mediated uptake. 99mTc-HABN microSPECT imaging resulted in clear delineation of the tumor. 99mTc-HABN is a novel BN-based radiopharmaceutical that proved to be suitable for targeted imaging of prostate cancer with microSPECT using the human prostate cancer cell line PC-3 in a xenograft mouse model.Keywords
This publication has 43 references indexed in Scilit:
- In Vitro and In Vivo Evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor–Expressing Prostate CancerJournal of Nuclear Medicine, 2011
- Optimization, biological evaluation and microPET imaging of copper-64-labeled bombesin agonists, [64Cu-NO2A-(X)-BBN(7–14)NH2], in a prostate tumor xenografted mouse modelNuclear Medicine and Biology, 2010
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analoguesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- Positron emission tomography imaging of prostate cancerAmino Acids, 2009
- New Agents and Techniques for Imaging Prostate CancerJournal of Nuclear Medicine, 2009
- Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluationNuclear Medicine and Biology, 2009
- Improving Tumor-Targeting Capability and Pharmacokinetics of 99mTc-Labeled Cyclic RGD Dimers with PEG4 LinkersMolecular Pharmaceutics, 2008
- Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studiesNuclear Medicine and Biology, 2008
- Bombesin, calcitonin and leu-enkephalin immunoreactivity in endocrine cells of human lungCellular and Molecular Life Sciences, 1981